• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.44% Nasdaq Down0.37%

    AcelRx Pharmaceuticals, Inc. (ACRX)

    5.72 Up 0.10(1.78%) 4:00PM EST
    ProfileGet Profile for:
    AcelRx Pharmaceuticals, Inc.
    351 Galveston Drive
    Redwood City, CA 94063
    United States - Map
    Phone: 650-216-3500
    Fax: 650-216-6500
    Website: http://www.acelrx.com

    Index Membership:N/A
    Industry:Medical Appliances & Equipment
    Full Time Employees:32

    Business Summary 

    AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes therapies for the treatment of acute pain. The company’s lead product candidate is Zalviso, an investigational, pre-programmed, non-invasive, handheld system that has completed Phase III clinical trials for the treatment of moderate-to-severe acute pain in the hospital setting. The company is also developing ARX-04, a sufentanil single-dose tablet, which has been planned to initiate Phase III clinical trials for the treatment of moderate-to-severe acute pain to be administered by a healthcare professional to a patient in settings of acute pain, such as in the emergency room, hospital floor, ambulatory care facilities, or on the battlefield. In addition, its product candidate pipeline consists of ARX-02, a pain management system that has completed Phase II clinical trials for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a single, fixed-dose, and combination drug product, which has been completed Phase II clinical trial designed to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician’s office. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on AcelRx Pharmaceuticals, Inc.

    Corporate Governance 
    AcelRx Pharmaceuticals, Inc.’s ISS Governance QuickScore as of Jul 1, 2015 is 8. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 8.
    Brought to you by Institutional Shareholder Services (ISS)

    Key Executives 
    Mr. Howard B. Rosen , 57
    Interim Chief Exec. Officer and Independent Director
    Dr. Pamela P. Palmer M.D., Ph.D., 52
    Co-Founder, Chief Medical Officer and Director
    Mr. Timothy E. Morris CPA, 53
    Chief Financial Officer and Head of Bus. Devel.
    Mr. Lawrence G. Hamel , 63
    Chief Devel. Officer
    Mr. Anil N. Dasu , 52
    Chief Engineering Officer
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders